Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Forest acquires all rights held by Gruenenthal for colistin

The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.

20 Dec 2010

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.

20 Dec 2010

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.

19 Dec 2010

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

Families who were facing the prospect of huge increases in the cost of life-saving drugs for their children can breath easier thanks to a new law that will preserve discounts on specialized, so-called "orphan drugs."

17 Dec 2010

Tampa Hospital associates receive Transplant Excellence Award for lung transplant program

New Lung Associates PA and the Lung Transplant Program at Tampa General Hospital have received HealthGrades 2011 Organ Transplant Excellence Award. The award places Tampa General Hospital among the top three lung transplant programs in the nation.

16 Dec 2010

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA BioSciences, Inc. announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier.

15 Dec 2010

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has been awarded a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA), a component of the Department of Defense (DOD), focused on identifying and advancing novel technologies to support defense of our nation's soldiers and civilian population.

14 Dec 2010

Santen launches DIQUAS Ophthalmic Solution in Japan

Inspire Pharmaceuticals, Inc. announced that DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) received pricing approval and was launched for sale today in Japan by its partner, Santen Pharmaceutical Co., Ltd. Inspire will receive a related milestone payment of $1.25 million in the fourth quarter of 2010 and is also entitled to receive payments based upon a tiered royalty rate on net sales of DIQUAS in Japan, with a minimum rate in the high single digits and a maximum rate in the low double digits.

From Santen Pharmaceutical Co., Ltd. 13 Dec 2010

New initiative launched to fight cystic fibrosis

The University of British Columbia, in partnership with the Canadian Cystic Fibrosis Foundation (CCFF) and the Centre for Drug Research and Development (CDRD), today launches the Cystic Fibrosis Technology Initiative (CFTI) to advance Canadian technologies that will help combat cystic fibrosis (CF).

13 Dec 2010

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.

7 Dec 2010

New analysis shows that common diseases are not lined to genetic factors

The case for a substantial role of genes in susceptibility to the major human diseases is now scientifically refuted argues a groundbreaking new analysis published by the public interest science organization, The Bioscience Resource Project.

7 Dec 2010

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

At the prestigious annual British Thoracic Society meeting in London on December 1st, Dr Caroline Baxter reported the highly sensitive performance of Myconostica's real-time PCR assay MycAssayTM Aspergillus in cystic fibrosis sputum which is 260% more sensitive than the currently used culture.

6 Dec 2010

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

The interest in the biological effects of non-ionizing Electro Magnetic Fields (EMFs) and Static Magnetic Fields (SMFs) on the whole organism, as well on cellular systems, has noticeably increased in recent years in consideration of their increased production (from the generation and transmission of electricity, to domestic appliances and industrial equipment, to telecommunications and broadcasting) and the possible health risk for humans.

4 Dec 2010

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

1 Dec 2010

Study finds solution for debate about mutation testing to prevent children with cystic fibrosis

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).

From Quest Diagnostics 24 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

New investigational drug improves lung function in CF patients

An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.

17 Nov 2010

New method to improve coordinating care in children with chronic conditions

Children with chronic health conditions such as cystic fibrosis, type 1 diabetes, sickle cell diseases and cerebral palsy represent less than two percent of the population but can consume more than 50 percent of resources at children's hospitals throughout the country. Coordinating care for these children has historically been difficult because hospitals have varying methods to identify them in their systems.

17 Nov 2010

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

A common transmissible strain of the bacteria Pseudomonas aeruginosa has been identified among cystic fibrosis (CF) patients in Canada, suggesting that cross-infection has occurred widely between CF centers in the United Kingdom and Canada, according to a study in the November 17 issue of JAMA. Infection with this strain among Canadian CF patients has been associated with an increased risk of death or lung transplantation.

17 Nov 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Forest acquires all rights held by Gruenenthal for colistin

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

Tampa Hospital associates receive Transplant Excellence Award for lung transplant program

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Santen launches DIQUAS Ophthalmic Solution in Japan

New initiative launched to fight cystic fibrosis

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

New analysis shows that common diseases are not lined to genetic factors

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Study finds solution for debate about mutation testing to prevent children with cystic fibrosis

Vertex submits NDA for telaprevir for treating hepatitis C

VX-770 drug candidate improves lung function in people with cystic fibrosis

New investigational drug improves lung function in CF patients

New method to improve coordinating care in children with chronic conditions

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in